X4 Pharmaceuticals’ (XFOR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report report published on Friday,Benzinga reports. They currently have a $1.50 target price on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2028 earnings at $0.02 EPS and FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus cut their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $0.53 on Friday. The company has a market cap of $90.39 million, a P/E ratio of -5.89 and a beta of 0.12. The business has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.60. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Insider Activity

In other news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 202,663 shares of company stock valued at $91,198. Company insiders own 1.62% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. State Street Corp raised its stake in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after buying an additional 81,968 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in X4 Pharmaceuticals during the third quarter valued at approximately $340,000. AQR Capital Management LLC raised its stake in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after buying an additional 388,115 shares in the last quarter. Finally, Barclays PLC grew its position in shares of X4 Pharmaceuticals by 196.0% in the 3rd quarter. Barclays PLC now owns 277,682 shares of the company’s stock worth $185,000 after acquiring an additional 183,861 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.